Investment Thesis
Protalix demonstrates exceptional financial health with strong cash reserves ($41M), minimal debt, and robust free cash flow generation ($21.3M), but operational fundamentals are concerning with declining revenue (-1.2% YoY), critically low gross margins (0.6%), and apparent recovery from a significant prior-year loss rather than sustainable profit growth.
Strengths
- Strong balance sheet with $41M cash and 0.01x debt-to-equity ratio
- Excellent liquidity metrics (3.15x current ratio) providing downside protection
- Positive free cash flow of $21.3M with 63% FCF margin demonstrating cash generation capability
- High ROE (27.2%) and ROA (17.9%) metrics reflecting efficient capital deployment
- Minimal long-term debt ($912K) limiting financial risk
Risks
- Declining revenue trajectory (-1.2% YoY) in a competitive biotech sector
- Unsustainably low gross margin of 0.6% indicating severe product/operational challenges
- Massive net income decline of -325% YoY suggests comparison to prior-year loss with questionable profit sustainability
- Disconnect between gross profit ($198K) and operating income ($21.1M) implies reliance on non-operating gains
- Zero insider Form 4 filings in 90 days suggests lack of management conviction
Key Metrics to Watch
- Revenue growth acceleration or stabilization
- Gross margin expansion toward industry-standard levels (>40% for biotech)
- Sustainability of operating cash flow as revenue trends evolve
- R&D pipeline progress and new product commercialization
- Source and sustainability of non-operating gains driving profitability
Financial Metrics
Revenue
33.8M
Net Income
18.3M
EPS (Diluted)
$0.22
Free Cash Flow
21.3M
Total Assets
102.3M
Cash
41.0M
Profitability Ratios
Gross Margin
0.6%
Operating Margin
62.7%
Net Margin
54.3%
ROE
27.2%
ROA
17.9%
FCF Margin
63.0%
Balance Sheet & Liquidity
Current Ratio
3.15x
Quick Ratio
2.04x
Debt/Equity
0.01x
Debt/Assets
34.3%
Interest Coverage
5.96x
Long-term Debt
912.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:25:50.910870 |
Data as of: 2026-03-31 |
Powered by Claude AI